DE60042598D1 - Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist. - Google Patents

Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.

Info

Publication number
DE60042598D1
DE60042598D1 DE60042598T DE60042598T DE60042598D1 DE 60042598 D1 DE60042598 D1 DE 60042598D1 DE 60042598 T DE60042598 T DE 60042598T DE 60042598 T DE60042598 T DE 60042598T DE 60042598 D1 DE60042598 D1 DE 60042598D1
Authority
DE
Germany
Prior art keywords
fibromyalgia
irritant
medicaments
syndrome
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042598T
Other languages
English (en)
Inventor
David F Horrobin
Cari Loder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarin Neuroscience Ltd
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Application granted granted Critical
Publication of DE60042598D1 publication Critical patent/DE60042598D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
DE60042598T 1999-10-12 2000-10-12 Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist. Expired - Lifetime DE60042598D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9924172A GB2355191A (en) 1999-10-12 1999-10-12 Combination formulations for fatigue, head injury and strokes
PCT/GB2000/003926 WO2001026623A2 (en) 1999-10-12 2000-10-12 Treatment of fatigue, head injury and stroke

Publications (1)

Publication Number Publication Date
DE60042598D1 true DE60042598D1 (de) 2009-09-03

Family

ID=10862624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042598T Expired - Lifetime DE60042598D1 (de) 1999-10-12 2000-10-12 Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.

Country Status (15)

Country Link
US (1) US6441038B1 (de)
EP (1) EP1220689B1 (de)
AU (1) AU782656B2 (de)
CA (1) CA2388377C (de)
CZ (1) CZ20021197A3 (de)
DE (1) DE60042598D1 (de)
GB (1) GB2355191A (de)
HR (1) HRP20020309A2 (de)
HU (1) HUP0203470A3 (de)
MX (1) MXPA02003724A (de)
NO (1) NO20021716L (de)
NZ (1) NZ518306A (de)
PL (1) PL354975A1 (de)
SK (1) SK4672002A3 (de)
WO (1) WO2001026623A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1459750E (pt) 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030176773A1 (en) * 2002-03-12 2003-09-18 Gendreau Roger Michael Methods of assessing the level of a subjective symptom
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
WO2004016261A1 (en) * 2002-08-12 2004-02-26 Yuuichi Murayama Method for suppressing proliferation of abnormal prion protein with leucine, isoleucine or valine
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050272805A1 (en) * 2002-11-19 2005-12-08 Detke Michael J Treatment of gastrointestinal disorders with duloxetine
EP1567163B1 (de) * 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
DE602004015257D1 (de) 2003-02-14 2008-09-04 Pf Medicament Verwendung von dem (1s,2r)-milnacipran-enantiomer zur herstellung eines arzneimittels
ATE365554T1 (de) 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
PL3138566T3 (pl) 2003-11-17 2022-03-07 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii z użyciem bh4
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
RU2007103313A (ru) * 2004-08-03 2008-09-10 ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) Комбинация бупропина и другого состава для эффективной потери веса
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
AU2005313940A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TW200803901A (en) * 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
JP2009518415A (ja) * 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド 疾患の処置のための方法および組成物
US20090306050A1 (en) * 2006-02-03 2009-12-10 Timothy Dinan Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008033299A2 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
WO2008042773A2 (en) * 2006-09-29 2008-04-10 Pdxrx, Inc. Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
PL3461503T3 (pl) 2007-04-11 2022-05-02 Biomarin Pharmaceutical Inc. Sposoby podawania tetrahydrobiopteryny, związane z nią kompozycie i sposoby pomiaru
ES2577477T3 (es) 2007-05-01 2016-07-15 Concert Pharmaceuticals Inc. Compuestos morfinanos
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
DK2397158T3 (en) * 2008-10-30 2016-07-25 Concert Pharmaceuticals Inc COMBINATION OF MORPHINANFORBINDELSER AND antidepressants in treating pseudobulbar affect
EP2496079A4 (de) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas Neue kristalline formen von (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenylcyclopropancarboxamid
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
EP3248653A1 (de) * 2011-06-24 2017-11-29 K-Pax Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von chronischer müdigkeit
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
RU2493839C1 (ru) * 2012-02-28 2013-09-27 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения синдрома хронической усталости
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020160263A1 (en) * 2019-01-30 2020-08-06 Synlev Pharmaceuticals Corporation Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431670A (en) * 1980-12-19 1984-02-14 Bernardo Heller D-Phenylalanine treatment
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
PT784476E (pt) * 1994-10-05 2003-03-31 Cari Loder Tratamento da esclerose multipla (em) e outras condicoes desmielinizantes utilizando lofepramina em combinacao com l-fenilalanina tirosina ou triptofano e opcionalmente um composto da vitamina b 12
GB2297868B (en) 1995-02-07 1999-04-28 Nokia Mobile Phones Ltd A shielding device
JP3128609B2 (ja) 1996-02-01 2001-01-29 株式会社小糸製作所 車輌用灯具の照射方向制御装置
DE69715899T2 (de) * 1996-07-05 2003-05-28 Wwk Trust Kent Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
US5765240A (en) * 1996-07-31 1998-06-16 L&P Property Management Co. Spring bedding product collapsible in the transverse direction, and method of making it
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment

Also Published As

Publication number Publication date
CA2388377A1 (en) 2001-04-19
WO2001026623A3 (en) 2001-06-21
EP1220689A2 (de) 2002-07-10
AU782656B2 (en) 2005-08-18
EP1220689B1 (de) 2009-07-22
AU7932800A (en) 2001-04-23
NO20021716L (no) 2002-06-10
CA2388377C (en) 2011-02-01
HRP20020309A2 (en) 2004-02-29
MXPA02003724A (es) 2003-10-14
GB2355191A (en) 2001-04-18
WO2001026623A2 (en) 2001-04-19
NO20021716D0 (no) 2002-04-11
CZ20021197A3 (cs) 2002-09-11
GB9924172D0 (en) 1999-12-15
PL354975A1 (en) 2004-03-22
NZ518306A (en) 2004-04-30
HUP0203470A3 (en) 2005-10-28
SK4672002A3 (en) 2002-09-10
HUP0203470A2 (hu) 2003-02-28
US6441038B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
DE60109044D1 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DE69916686D1 (de) Gerät zur Behandlung von Atemstillstand im Schlaf
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60115872D1 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE307607T1 (de) Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
BR0202519B1 (pt) métodos para tratamento de material de madeira e para tratamento microbicida de material de madeira.
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
DE60021065D1 (de) Virus behandlung
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE288279T1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE60011060D1 (de) Virus behandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition